ATE296351T1 - Cck-2, eine rezeptor tyrosin kinase - Google Patents

Cck-2, eine rezeptor tyrosin kinase

Info

Publication number
ATE296351T1
ATE296351T1 AT95900749T AT95900749T ATE296351T1 AT E296351 T1 ATE296351 T1 AT E296351T1 AT 95900749 T AT95900749 T AT 95900749T AT 95900749 T AT95900749 T AT 95900749T AT E296351 T1 ATE296351 T1 AT E296351T1
Authority
AT
Austria
Prior art keywords
mck
receptor tyrosine
relates
tyrosine kinase
cck
Prior art date
Application number
AT95900749T
Other languages
English (en)
Inventor
Axel Ullrich
Frauke H E Alves
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22547060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE296351(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE296351T1 publication Critical patent/ATE296351T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95900749T 1993-11-16 1994-11-16 Cck-2, eine rezeptor tyrosin kinase ATE296351T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/153,397 US6051397A (en) 1993-11-16 1993-11-16 DNA encoding MCK-10, a novel receptor tyrosine kinase
PCT/EP1994/003799 WO1995014089A2 (en) 1993-11-16 1994-11-16 Cck-2, a receptor tyrosine kinase

Publications (1)

Publication Number Publication Date
ATE296351T1 true ATE296351T1 (de) 2005-06-15

Family

ID=22547060

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95900749T ATE296351T1 (de) 1993-11-16 1994-11-16 Cck-2, eine rezeptor tyrosin kinase

Country Status (10)

Country Link
US (4) US6051397A (de)
EP (1) EP0909315B1 (de)
AT (1) ATE296351T1 (de)
AU (2) AU8143994A (de)
CA (1) CA2187152A1 (de)
DE (1) DE69434385T2 (de)
DK (1) DK0909315T3 (de)
ES (1) ES2242956T3 (de)
PT (1) PT909315E (de)
WO (2) WO1995014089A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627733B2 (en) 1993-06-14 2003-09-30 Jeffrey D. Johnson Receptor tyrosine kinase with a discoidin-type binding domain
AU697142B2 (en) * 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
US6022694A (en) * 1997-04-04 2000-02-08 Regeneron Pharmaceuticals, Inc. Assay for ligands to tyrosine kinase receptors
US6482607B1 (en) * 1998-06-16 2002-11-19 Rmf Dictagene S.A. Expression vector for use in a one-step purification protocol
GB9820392D0 (en) 1998-09-19 1998-11-11 Eastman Kodak Co Novel yellow couplers providing images with improved sharpness and photographic elements containing them
AUPQ873300A0 (en) * 2000-07-12 2000-08-03 Medvet Science Pty. Ltd. A binding motif of a receptor (2)
EP1218404A4 (de) * 1999-09-15 2004-04-07 Medvet Science Pty Ltd Rezeptor-bindungsmotiv
GB2357084A (en) * 1999-12-06 2001-06-13 Amersham Pharm Biotech Uk Ltd A hydrophobic carrier peptide
US20090176722A9 (en) * 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
US6365355B1 (en) 2000-03-28 2002-04-02 The Regents Of The University Of California Chimeric proteins for detection and quantitation of DNA mutations, DNA sequence variations, DNA damage and DNA mismatches
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
EP1356048A2 (de) * 2000-12-04 2003-10-29 Argonex Pharmaceuticals Zytotoxisch t-lymphozyte induzierende immunogene zur krebsvorbeugung,behandlung, und diagnose
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20070025997A1 (en) * 2002-04-03 2007-02-01 Usha Nagavarapu Use of biomolecular targets in the treatment and visualization of brain tumors
CA2544074A1 (en) * 2003-10-24 2005-05-06 Esbatech Ag Method for the identification and/or validation of receptor tyrosine kinase inhibitors
US20090142345A1 (en) * 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
WO2008070090A2 (en) * 2006-12-05 2008-06-12 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2518157A1 (de) 2011-04-26 2012-10-31 Sanofi Testsysteme und Verfahren zur Identifizierung einer Verbindung, die die zelluläre DDR-Aktivität verändert
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2013155365A1 (en) * 2012-04-12 2013-10-17 University Of Maryland Markers for diagnosing amyotrophic lateral sclerosis
EP2935249B1 (de) 2012-12-19 2018-12-12 Novartis AG Autotaxinhemmer
KR101462329B1 (ko) 2013-01-30 2014-11-21 중앙대학교 산학협력단 디스코이딘 도메인 리셉터 2의 ｊｍ2 도메인의 발현 촉진제를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물
EP3022201A1 (de) 2013-07-18 2016-05-25 Novartis AG Autotaxinhemmer
PT3022202T (pt) 2013-07-18 2019-09-03 Novartis Ag Inibidores da autotaxina compreendendo um núcleo beteroaromático anel-benzilo-amida-ciclo
US20170037030A1 (en) 2014-04-24 2017-02-09 Novartis Ag Autotaxin inhibitors
WO2019071262A1 (en) * 2017-10-06 2019-04-11 The Regents Of The University Of California RAPID SITU DETECTION OF DNA AND RNA
MX2022007353A (es) 2019-12-17 2022-09-19 Univ Texas Anticuerpos novedosos ddr1 y sus usos.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004606A (en) * 1986-09-24 1991-04-02 Hybritech Incorporated Non-covalent antibody-anthracycline immunocomplexes
NL8900529A (nl) 1989-03-03 1990-10-01 Eurodiagnostics B V Werkwijze en kit voor het bepalen van tyrosine fosforylerende en defosforylerende activiteit.
CA2062377A1 (en) 1991-03-21 1992-09-22 Mariano Barbacid Method for detection of neuroactive substances
GB9314271D0 (en) * 1993-07-09 1993-08-18 Inst Of Cancer The Research Cell growth factor receptors
AU697142B2 (en) 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse

Also Published As

Publication number Publication date
CA2187152A1 (en) 1995-05-26
US6897029B1 (en) 2005-05-24
AU8143994A (en) 1995-06-06
US5677144A (en) 1997-10-14
US6051397A (en) 2000-04-18
EP0909315A2 (de) 1999-04-21
PT909315E (pt) 2005-10-31
EP0909315B1 (de) 2005-05-25
DE69434385D1 (de) 2005-06-30
ES2242956T3 (es) 2005-11-16
WO1995014089A2 (en) 1995-05-26
DK0909315T3 (da) 2005-09-12
AU8143894A (en) 1995-06-06
DE69434385T2 (de) 2006-05-24
US20060147372A1 (en) 2006-07-06
WO1995014088A1 (en) 1995-05-26
WO1995014089A3 (en) 1995-06-15

Similar Documents

Publication Publication Date Title
DE69434385D1 (de) Cck-2, eine rezeptor tyrosin kinase
TWI262914B (en) Compounds and pharmaceutical compositions for inhibiting protein kinases
AP1486A (en) Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use.
NO985376D0 (no) Kinolinkarboksamider som TNF-inhibitorer og som PDA-IV inhibitorer
ATE215601T1 (de) Rezeptoren der steroid/thyroid superfamilie von rezeptoren
AP2001002341A0 (en) Diaminothiazoles and their use for inhibiting protein kinases.
DE69233478D1 (de) Neue menschliche cdc25 gene, kodierte produkte und ihre verwendung
MXPA06001193A (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular.
DK1955700T3 (da) Terapeutisk behandling af androgenreceptor-betingede lidelser
MXPA05010035A (es) Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
PT662137E (pt) Transcricao de genes e radiacao ionizante: metodos e composicoes
NO995817D0 (no) Kinolin- og kinoksalin-forbindelser som inhiberer blodplateavledet vekstfaktor og/eller P561ck-tyrosinkinase
TR199700644T1 (xx) Serotonin-ili�kili sistemler �zerinde etkiye sahip bile�ikler.
NO20001598D0 (no) Apolipoprotein A-1-agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser
BR0308339A (pt) Indazóis substituìdos com uma atividade anticancerosa
TR200003514T2 (tr) Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
EP1383919A4 (de) Verfahren und zusammensetzungen zur verwendung von mhc-klasse ii-invariante-kette-polypeptid als rezeptor für makrophagenwanderung-hemmfaktor
ATE179211T1 (de) Menschliche il-3-varianten
ATE279515T1 (de) Pct-65 serotonin rezeptor
DE60016405D1 (de) Neurodegenerative-erkrankung verwandtes gen
DE3767287D1 (de) Potenzierung von prazosin.
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
ATE252636T1 (de) Klonierung und expression von dem beta app-c100 rezeptor
ATE250030T1 (de) Peptidverbindungen mit mmp- und tnf-hemmender wirkung
ATE382637T1 (de) Rezeptor-tyrosine-kinase gene

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0909315

Country of ref document: EP

REN Ceased due to non-payment of the annual fee